To overcome the suppression of CTL antitumor effects, which occur due to tumor cell heterogeneity, we previously focused on a peptide vaccine targeting the tumor vasculature in the tumor microenvironment and demonstrated the safety and immunogenicity of vaccination with synthetic peptides for vascular endothelial growth factor receptor (VEGFR) epitopes in recurrent HGG patients [11]. This evidence concerns the gene KDR and neoplasm.